Sodium-Glucose Transporter 2 Inhibitors: all 1,276 studies that test it

Page 5 of 13. Open to participants first (266), then studies with results posted, then the rest; newest registration first within each.

• Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin InfusionCompletedNCT02673138Not applicableResults posted
• Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart FailureCompletedNCT02653482Phase 4Results posted
• EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)CompletedNCT02635386Phase 3Results posted
• Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN StudyCompletedNCT02632747Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)CompletedNCT02630706Phase 3Results posted
• Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes MellitusCompletedNCT02622113Phase 4Results posted
• ESR-15-11293 - Saxa/Dapa, Safety and Efficacy StudyCompletedNCT02613897Not applicableResults posted
• Effect of Dapagliflozin on Inflammation and Endothelial FunctionTerminatedNCT02608905Phase 4Results posted
• SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2CompletedNCT02592421Phase 3Results posted
• Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT02589639Phase 4Results posted
• Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RACompletedNCT02589626Phase 4Results posted
• The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DMCompletedNCT02582840Phase 1Results posted
• The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DMCompletedNCT02582814Phase 3Results posted
• Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)CompletedNCT02580591Phase 3Results posted
• Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed ConditionsCompletedNCT02577315Phase 1Results posted
• Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)CompletedNCT02577003Phase 3Results posted
• Foxiga Korea Local Phase 4 StudyCompletedNCT02564926Phase 4Results posted
• Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)CompletedNCT02564211Phase 3Results posted
• Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With ForxigaCompletedNCT02561130Phase 4Results posted
• Bexagliflozin Efficacy and Safety TrialCompletedNCT02558296Phase 3Results posted
• A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKDCompletedNCT02547935Phase 2/3Results posted
• A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy AloneCompletedNCT02531035Phase 3Results posted
• Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?TerminatedNCT02520518Phase 2Results posted
• Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 DiabetesCompletedNCT02518945Phase 3Results posted
• Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes MellitusCompletedNCT02489968Phase 3Results posted
• Vildagliptin Versus Dapagliflozin on GlucagonCompletedNCT02475070Phase 4Results posted
• Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With SulphonylureaCompletedNCT02471404Phase 4Results posted
• Effect of LIK066 on Body Weight in Patients With Elevated Body Mass IndexCompletedNCT02470403Phase 2Results posted
• Pharmacogenetics of SGLT2 InhibitorsTerminatedNCT02462421Phase 4Results posted
• Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 DiabetesCompletedNCT02460978Phase 3Results posted
• Dose-ranging Study in Patients With Type 1 Diabetes MellitusCompletedNCT02459899Phase 2Results posted
• An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of DapagliflozinCompletedNCT02433678Phase 4Results posted
• Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes MellitusCompletedNCT02426541Phase 4Results posted
• Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyCompletedNCT02421510Phase 3Results posted
• A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin AloneCompletedNCT02419612Phase 3Results posted
• Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)CompletedNCT02414958Phase 3Results posted
• A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 DiabetesCompletedNCT02413398Phase 3Results posted
• A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes MellitusCompletedNCT02390050Phase 2Results posted
• Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyCompletedNCT02384941Phase 3Results posted
• Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1CCompletedNCT02383940Phase 2Results posted
• Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?CompletedNCT02371187Phase 2Results posted
• Mechanisms of Weight Loss With SGLT2 InhibitionCompletedNCT02360774Phase 4Results posted
• Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)CompletedNCT02354235Phase 3Results posted
• Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic PatientsCompletedNCT02324842Not applicableResults posted
• Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy AloneCompletedNCT02284893Phase 3Results posted
• A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic PatientsCompletedNCT02279407Phase 2Results posted
• Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 DiabetesCompletedNCT02268214Phase 3Results posted
• Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and FemaleCompletedNCT02266472Phase 1Results posted
• Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese ParticipantsCompletedNCT02243202Phase 2Results posted
• Dapagliflozin Effects on Epicardial FatCompletedNCT02235298Phase 4Results posted
• Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy SubjectsCompletedNCT02230995Phase 1Results posted
• Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes MellitusCompletedNCT02227849Phase 4Results posted
• Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)CompletedNCT02226003Phase 3Results posted
• Bioequivalence Study Coadministered to Healthy Subjects in the Fasted StateCompletedNCT02223065Phase 1Results posted
• Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes MellitusCompletedNCT02220920Phase 4Results posted
• Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 DiabetesCompletedNCT02220907Phase 3Results posted
• Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.CompletedNCT02157298Phase 4Results posted
• A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)CompletedNCT02139943Phase 2Results posted
• Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)CompletedNCT02115347Phase 1Results posted
• Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin SecretionCompletedNCT02113241Phase 2/3Results posted
• Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single TabletsCompletedNCT02106923Phase 1Results posted
• Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese VolunteersCompletedNCT02102932Phase 1Results posted
• Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)CompletedNCT02099110Phase 3Results posted
• Phase III Insulin Add-On Asia Regional Program - STCompletedNCT02096705Phase 3Results posted
• Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic NephropathyCompletedNCT02065791Phase 3Results posted
• Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)CompletedNCT02036515Phase 3Results posted
• A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).CompletedNCT02033889Phase 3Results posted
• Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate TabletsCompletedNCT02028767Phase 1Results posted
• A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and SitagliptinCompletedNCT02025907Phase 4Results posted
• Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)CompletedNCT01999218Phase 3Results posted
• A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes MellitusCompletedNCT01989754Phase 4Results posted
• Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)CompletedNCT01986881Phase 3Results posted
• A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)CompletedNCT01986855Phase 3Results posted
• Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single TabletsCompletedNCT01975220Phase 1Results posted
• A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)CompletedNCT01958671Phase 3Results posted
• Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)CompletedNCT01948986Phase 1Results posted
• Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT01947855Phase 3Results posted
• Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive AgentsCompletedNCT01939496Phase 4Results posted
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 TabletsCompletedNCT01924767Phase 1Results posted
• Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes MellitusCompletedNCT01915849Phase 1/2Results posted
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal ImpairmentCompletedNCT01907113Phase 1Results posted
• Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy ControlsCompletedNCT01867307Phase 2Results posted
• Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single TabletsCompletedNCT01844531Phase 1Results posted
• Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered TogetherCompletedNCT01811953Phase 1Results posted
• A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and ExerciseCompletedNCT01809327Phase 3Results posted
• Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 DiabetesCompletedNCT01778049Phase 3Results posted
• Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes MellitusCompletedNCT01742208Phase 2Results posted
• Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 DiabetesCompletedNCT01734785Phase 3Results posted
• Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular EventsCompletedNCT01730534Phase 3Results posted
• Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single TabletsCompletedNCT01672788Phase 1Results posted
• Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy ParticipantsCompletedNCT01662999Phase 1Results posted
• A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin TherapyCompletedNCT01649297Phase 2Results posted
• Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 DiabetesCompletedNCT01646320Phase 3Results posted
• Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and ProbenecidCompletedNCT01634100Phase 1Results posted
• Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 DiabetesCompletedNCT01606007Phase 3Results posted
• Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 DiabetesCompletedNCT01581658Phase 1Results posted
• PK Study of Dapagliflozin in Pediatric Subjects With T2DMCompletedNCT01525238Phase 1Results posted
• A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal ImpairmentCompletedNCT01512849Phase 1Results posted
• BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 DiabetesCompletedNCT01498185Phase 2Results posted
• Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.CompletedNCT01451775Phase 1Results posted

← Sodium-Glucose Transporter 2 Inhibitors overview